User profiles for Solange Peters
 | solange petersVerified email at chuv.ch Cited by 57410 |
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed
cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-…
cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-…
[HTML][HTML] Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
S Peters, DR Camidge, AT Shaw… - … England Journal of …, 2017 - Mass Medical Soc
Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …
[HTML][HTML] First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
…, S Nair, R Juergens, S Peters… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …
[HTML][HTML] Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic …
Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs)
during therapy with immune checkpoint inhibitors are at risk for developing severe …
during therapy with immune checkpoint inhibitors are at risk for developing severe …
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
…, G de Lima Lopes, P Grivas, CA Painter, S Peters… - The Lancet, 2020 - thelancet.com
Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
[HTML][HTML] 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
…, S Peters, P Members, R Stahel, E Felip, S Peters… - Annals of …, 2015 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[HTML][HTML] Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4),
anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) …
anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) …
[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
…, S Peters, E Felip, R Stahel, E Felip, S Peters… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[HTML][HTML] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
…, S Peters, E Felip, R Stahel, E Felip, S Peters… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second ESMO …
consensus conferences to focus on specific issues in each type of tumour. The Second ESMO …
[HTML][HTML] Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
…, I Albert, A Vergnenegre, S Peters… - … England Journal of …, 2019 - Mass Medical Soc
Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …